Takeda Pharmaceutical Co. Ltd. Makes New Investment in Shattuck Labs, Inc. (NASDAQ:STTK)

Takeda Pharmaceutical Co. Ltd. purchased a new position in shares of Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 515,619 shares of the company's stock, valued at approximately $624,000. Shattuck Labs accounts for 2.3% of Takeda Pharmaceutical Co. Ltd.'s portfolio, making the stock its 5th biggest holding. Takeda Pharmaceutical Co. Ltd. owned 1.08% of Shattuck Labs at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in STTK. Geode Capital Management LLC lifted its holdings in Shattuck Labs by 0.9% in the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company's stock valued at $3,184,000 after acquiring an additional 8,133 shares during the period. Atom Investors LP acquired a new stake in shares of Shattuck Labs in the third quarter valued at about $35,000. JPMorgan Chase & Co. boosted its holdings in Shattuck Labs by 63.2% during the third quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company's stock worth $96,000 after buying an additional 10,667 shares in the last quarter. Readystate Asset Management LP acquired a new position in Shattuck Labs during the third quarter worth about $39,000. Finally, MetLife Investment Management LLC increased its holdings in Shattuck Labs by 129.1% in the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company's stock valued at $86,000 after buying an additional 13,859 shares in the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Leerink Partnrs raised Shattuck Labs to a "strong-buy" rating in a research note on Monday, March 17th. Leerink Partners assumed coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They set an "outperform" rating and a $4.00 target price on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Shattuck Labs in a research note on Thursday. Finally, HC Wainwright reissued a "neutral" rating on shares of Shattuck Labs in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $7.50.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK traded down $0.08 during trading on Monday, reaching $0.97. 45,698 shares of the company's stock traded hands, compared to its average volume of 376,984. The company has a 50 day moving average of $1.24 and a 200-day moving average of $1.46. Shattuck Labs, Inc. has a 12 month low of $0.94 and a 12 month high of $11.76. The stock has a market capitalization of $46.36 million, a P/E ratio of -0.63 and a beta of 1.66.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. Equities research analysts predict that Shattuck Labs, Inc. will post -1.48 earnings per share for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.